ResMed Capital Surpluse vs Current Deferred Revenue Analysis
RMD Stock | USD 235.44 11.77 4.76% |
ResMed financial indicator trend analysis is much more than just breaking down ResMed Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ResMed Inc is a good investment. Please check the relationship between ResMed Capital Surpluse and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Capital Surpluse vs Current Deferred Revenue
Capital Surpluse vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ResMed Inc Capital Surpluse account and Current Deferred Revenue. At this time, the significance of the direction appears to have very strong relationship.
The correlation between ResMed's Capital Surpluse and Current Deferred Revenue is 0.85. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of ResMed Inc, assuming nothing else is changed. The correlation between historical values of ResMed's Capital Surpluse and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of ResMed Inc are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Capital Surpluse i.e., ResMed's Capital Surpluse and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.85 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Capital Surpluse
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from ResMed's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ResMed Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, ResMed's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 451 M, whereas Issuance Of Capital Stock is forecasted to decline to about 49.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 2.0B | 2.4B | 2.6B | 2.7B | Total Revenue | 3.6B | 4.2B | 4.7B | 4.9B |
ResMed fundamental ratios Correlations
Click cells to compare fundamentals
ResMed Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ResMed fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 4.6B | 4.7B | 5.1B | 6.8B | 6.9B | 7.2B | |
Short Long Term Debt Total | 1.3B | 793.7M | 917.6M | 1.6B | 873.9M | 448.1M | |
Other Current Liab | 335.1M | 749.2M | 322.9M | 343.7M | 352.4M | 370.0M | |
Total Current Liabilities | 602.8M | 911.8M | 689.3M | 758.5M | 910.7M | 956.2M | |
Total Stockholder Equity | 2.5B | 2.9B | 3.4B | 4.1B | 4.9B | 5.1B | |
Property Plant And Equipment Net | 535.7M | 592.1M | 630.5M | 665.8M | 699.1M | 734.1M | |
Net Debt | 836.1M | 498.4M | 643.8M | 1.4B | 635.6M | 667.4M | |
Retained Earnings | 2.8B | 3.1B | 3.6B | 4.3B | 5.0B | 5.2B | |
Accounts Payable | 135.8M | 138.0M | 159.2M | 150.8M | 237.7M | 249.6M | |
Cash | 463.2M | 295.3M | 273.7M | 227.9M | 238.4M | 333.5M | |
Non Current Assets Total | 3.1B | 3.2B | 3.2B | 4.4B | 4.5B | 4.7B | |
Non Currrent Assets Other | 189.7M | 240.8M | 251.5M | 395.4M | 114.2M | 73.7M | |
Cash And Short Term Investments | 463.2M | 295.3M | 273.7M | 227.9M | 238.4M | 338.0M | |
Net Receivables | 474.6M | 614.3M | 576.0M | 704.9M | 837.3M | 879.1M | |
Common Stock Shares Outstanding | 145.7M | 146.5M | 147.0M | 147.5M | 147.6M | 147.7M | |
Liabilities And Stockholders Equity | 4.6B | 4.7B | 5.1B | 6.8B | 6.9B | 7.2B | |
Non Current Liabilities Total | 1.5B | 930.7M | 1.0B | 1.9B | 1.1B | 1.2B | |
Inventory | 416.9M | 457.0M | 743.9M | 998.0M | 822.3M | 863.4M | |
Other Current Assets | 168.7M | 208.2M | 337.9M | 437.0M | 459.8M | 482.8M | |
Other Stockholder Equity | (52.6M) | (1.1M) | 59.2M | 148.8M | 123.3M | 129.5M | |
Total Liab | 2.1B | 1.8B | 1.7B | 2.6B | 2.0B | 2.1B | |
Total Current Assets | 1.5B | 1.6B | 1.9B | 2.4B | 2.4B | 2.5B | |
Short Term Debt | 33.3M | 35.6M | 53.6M | 53.7M | 60.5M | 68.6M | |
Intangible Assets | 448.2M | 392.6M | 345.9M | 552.3M | 485.9M | 510.2M | |
Property Plant And Equipment Gross | 535.7M | 592.1M | 630.5M | 665.8M | 1.4B | 1.5B | |
Accumulated Other Comprehensive Income | (284.0M) | (193.5M) | (312.7M) | (272.5M) | (251.5M) | (239.0M) | |
Common Stock Total Equity | 571K | 575K | 580K | 583K | 670.5K | 417.0K | |
Common Stock | 580K | 583K | 586K | 588K | 676.2K | 443.7K | |
Other Assets | 145.6M | 240.8M | 202.3M | 261.3M | 300.5M | 315.5M | |
Good Will | 1.9B | 1.9B | 1.9B | 2.8B | 2.8B | 3.0B | |
Property Plant Equipment | 535.7M | 592.1M | 630.5M | 665.8M | 765.7M | 384.1M | |
Other Liab | 221.6M | 172.6M | 160.0M | 315.2M | 362.5M | 380.6M | |
Long Term Debt | 1.2B | 643.4M | 765.3M | 1.4B | 697.3M | 482.4M | |
Current Deferred Revenue | 98.6M | 109.6M | 108.7M | 138.1M | 152.6M | 160.2M | |
Net Tangible Assets | 158.5M | 565.2M | 1.1B | 807.3M | 726.5M | 632.7M | |
Long Term Debt Total | 1.3B | 1.2B | 643.4M | 765.3M | 880.1M | 737.7M | |
Capital Surpluse | 1.5B | 1.6B | 1.6B | 1.7B | 1.9B | 1.5B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.416 | Dividend Share 1.97 | Earnings Share 7.18 | Revenue Per Share 32.711 | Quarterly Revenue Growth 0.111 |
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.